Mutation of the p53 gene predicts lymph node metastases in Japanese patients with esophageal carcinoma: DNA and immunohistochemical analyses

Diseases of the Esophagus

Volumn 16, Issue 4, 2003, Pages 301-306

  Hattori, Kimiaki ^a   Kajiyama, Y ^a   Tsurumaru, M ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Clinicopathologic factors; Esophageal carcinoma; Immunohistochemistry; Multivariate analysis; Mutation; p53; Squamous cell carcinoma

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DNA ISOLATION; DNA SEQUENCE; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; JAPAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; SEQUENCE ANALYSIS, DNA;

EID: 0347285535     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2003.00351.x     Document Type: Article

References (25)

1. Akiyama H, Turumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-73.
2. Hollstein M, Sidransky D, Vogelstein B, Harris C C. P53 mutations in human cancers. Science 1991; 253: 49-53.
3. el-Deiry W S, Tokino T, Velculescu V E et al. WAF1, A potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
4. Miyashita T, Reed J C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
5. Levine A J, Momand J, Finaly C A. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
6. Lane D P. P53, guardian of the genome. Nature 1992; 358: 15-6.
7. Wagata T, Shibagaki I, Imamura M et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993; 53: 846-50.
8. Greenblatt M S, Bennett W P, Hollstein M, Harris C C. Mutations in p53 tumor suppressor gene: Clues to cancer aetiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
9. Iggo R, Gatter K, Bartek J, Lane D, Harris A L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
10. Japanese Society for Esophageal Diseases. Guide Lines for the Clinical and Pathologic Studies on Esophagus. 9th edn. Kanehara, Tokyo, 1999.
11. International Agency for Research on Cancer, The IARC data base of somatic p53 mutations in human tumors, available from http://www.iarc.fr./p53/homepage.htm.
12. Sigrid S, Mats I, Torbjorn N et al. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-82.
13. Taylor D, Koch W M, Zahurak M, Shah K, Sidransky D, Westra W H. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations. Hum Pathol 1999; 30: 1221-5.
14. Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
15. Oliner J D, Pietenpol J A, Thiagalingam S, Gyuris J, Kinzler K W, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
16. Wu X, Bayle J H, Olson D, Levine A J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32.
17. Honda R, Tanaka H, Tasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-7.
18. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database (Review). Nucleic Acids Res 1998; 26: 3453-9.
19. Taniere P, Martel-Planche G, Saurin J C et al. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. Br J Cancer 2001; 85: 721-6.
20. Shibagaki I, Tanaka H, Shimada Y et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res 1995; 1: 769-73.
21. Casson A G, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H. p53 alterations in oesophageal cancer association with clinicopathological features, risk factors, and survival. Mol Pathol 1998; 51: 71-9.
22. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-32.
23. Linderholm B K, Lindahl T, Holmberg L et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001; 61: 2256-60.
24. Uchida S, Shimada Y, Watanabe G et al. In oesophageal squamous cell carcinoma, vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998; 77: 1704-9.
25. Ravi R, Mookerjee B, Bhujwalla Z M et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha. Genes Dev 2000; 14: 34-44.